One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Beam Therapeutics Inc.
BEAM · NMS · Healthcare · Biotechnology
Current price
$25.16
52-week range
$20.23 - $38.26
Market cap
$2.60B
Balance sheet
Healthy
-8.77x Concerning
Net cash $800.00M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
3 Risks
1 rewards · 3 risks
- Reward Revenue grew 4.9% last year.
- Risk Operating margin compressed from -555.6% to -46033.2% over 3 years.
- Risk Return on equity was -11.3% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 1.2% (peer median: 4.6%).
What this company does
Beam Therapeutics Inc.
Beam Therapeutics is a company developing new medicines that fix genetic diseases at their root, like sickle cell disease. They make money by partnering with bigger drug companies and through grants to fund their research and development of these innovative treatments. This matters because if their new medicines prove successful, they could offer life-changing cures for people with serious illnesses.
How the company got here
Beam Therapeutics was founded in 2017 with a big idea: to use a revolutionary gene-editing technology called base editing to fix genetic diseases. Think of it like a super-precise spell-checker for DNA, correcting single "letters" in the genetic code that cause illness. The company quickly attracted attention and funding, allowing it to build a strong scientific team and a pipeline of potential treatments. Its early work focused on developing this groundbreaking technology and applying it to serious conditions that currently have limited treatment options.
What it actually does
Beam Therapeutics is a biotechnology company focused on creating "precision genetic medicines." These are not traditional drugs that you take to manage symptoms; instead, they aim to correct the underlying genetic cause of a disease. The company's technology allows it to make very specific changes to a person's DNA, essentially fixing the faulty gene. This approach is designed to offer one-time, potentially curative treatments for patients with severe genetic disorders.
Hematology and Genetic Disease Portfolio
This is Beam's primary focus, where it's developing treatments for serious inherited conditions. One key area is sickle cell disease, a blood disorder where red blood cells are misshapen, causing pain and other complications. Beam is working on a therapy called Ristoglogene autogetemcel, which involves modifying a patient's own stem cells to correct the genetic defect. They are also developing treatments for liver-targeting genetic diseases like alpha-1 antitrypsin deficiency and phenylketonuria (PKU), using a delivery system called lipid nanoparticles (LNPs) to get the genetic medicine to the right cells.
Platform Technologies
Beyond specific drug candidates, Beam is also developing the underlying technology that makes its medicines possible. This includes their "ESCAPE" platform, which combines a special type of cell conditioning with gene-edited stem cells to improve treatment effectiveness. They are also developing tools like anti-CD117 monoclonal antibodies, which help enable their ESCAPE platform. These platforms are crucial for advancing their pipeline and potentially treating a wider range of genetic diseases.
Collaborations and Partnerships
Beam Therapeutics doesn't work in isolation; it partners with larger pharmaceutical companies to advance its research and development. For instance, they have agreements with Pfizer to explore base editing for rare genetic diseases affecting the liver, muscles, and central nervous system. They also collaborate with Verve Therapeutics on cardiovascular disease treatments and with Orbital Therapeutics on designing RNA for various disease applications. These collaborations provide additional funding, expertise, and a pathway to potentially bring their therapies to more patients.
What management is betting on now
Management's core strategy revolves around advancing their most promising genetic medicine candidates through clinical trials and expanding their technology platforms. They are heavily invested in proving the safety and efficacy of their base editing approach in humans, particularly for blood disorders and liver diseases. A key priority is to successfully navigate the complex process of drug development, from early research to seeking regulatory approval. They are also focused on leveraging their partnerships to accelerate progress and explore new therapeutic areas where their precision genetic medicines can make a significant impact.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-79.33M
FY2025 Q1
$-106.95M
FY2025 Q2
$-79.59M
FY2025 Q3
$-86.49M
FY2025 Q4
$-87.02M
FY2026 Q1
$-130.75M
FY2026 Q2
$-68.51M
FY2026 Q3
$-111.96M
Revenue
$307.00K
Net income
$-134.41M
Diluted EPS
-1.28
Operating cash flow
$-110.75M
Free cash flow
$-111.96M
Fetching…
Sources
Revenue
$490.00K
Net income
$-122.68M
Diluted EPS
-1.18
Operating cash flow
$-66.10M
Free cash flow
$-68.51M
Fetching…
Sources
Revenue
$31.74M
Net income
$-94.32M
Diluted EPS
-0.91
Operating cash flow
$-128.51M
Free cash flow
$-130.75M
Fetching…
Sources
Revenue
$114.11M
Net income
$244.30M
Diluted EPS
2.53
Operating cash flow
$-83.29M
Free cash flow
$-87.02M
Fetching…
Sources
Revenue
$9.70M
Net income
$-112.73M
Diluted EPS
-1.10
Operating cash flow
$-81.48M
Free cash flow
$-86.49M
Fetching…
Sources
Revenue
$8.47M
Net income
$-102.29M
Diluted EPS
-1.00
Operating cash flow
$-76.45M
Free cash flow
$-79.59M
Fetching…
Sources
Revenue
$7.47M
Net income
$-109.27M
Diluted EPS
-1.24
Operating cash flow
$-103.88M
Free cash flow
$-106.95M
Fetching…
Sources
Revenue
$30.07M
Net income
$-90.35M
Diluted EPS
-1.09
Operating cash flow
$-76.36M
Free cash flow
$-79.33M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $25.16
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $800.0M - more cash than debt. Interest coverage -8.8x.
Net debt
$-800.00M
Interest coverage
-8.77x
Beam Therapeutics Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
BEAM
BASELINE
Beam Therapeutics Inc.
Total debt $243.87M Interest coverage -8.77x This is the baseline the peer rows are being compared against.
Total debt $230.14M Interest coverage -15.10x Neither company has much profit cushion over interest right now.
Total debt $15.51M Interest coverage -16.10x Neither company has much profit cushion over interest right now.
Total debt $112.48M Interest coverage -50.22x Neither company has much profit cushion over interest right now.
What you should know
The case for and against BEAM
1 Reward
3 Risks
Rewards
-
Revenue grew 4.9% last year.
Risks
-
Operating margin compressed from -555.6% to -46033.2% over 3 years.
-
Return on equity was -11.3% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 1.2% (peer median: 4.6%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-5.03x
P/B
2.63x
P/S
17.76x
EV/EBITDA
-5.11x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-178.9%
Operating margin
-46,033.2%
Net margin
-73.9%
ROE
-11.3%
ROA
-19.0%
Health
Liquidity and balance-sheet strength
Debt / equity
0.26x
Current ratio
13.01x
Quick ratio
12.72x
Total debt
$243.87M
Total cash
$1.04B
Growth
How the business has been compounding
Revenue TTM
$146.64M
Revenue 5Y CAGR
28.1%
EPS TTM
-0.87
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-388.65M
Free CF TTM
$-360.05M
FCF margin
-245.5%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—